https://biotechtv.com

BiotechTV | Bringing the Biotech Sector to LifeBiotechTV covers the biotechnology sector with news, stories, and educational videos.BiotechTV | Bringing the Biotech Sector to Life top of pageHomeQuick TakesAround KendallScience SpotlightBiotechTV UCompany NewsBright MindsShowsBiotech DirectBioVenture VoiCesBiotech CEO SisterhoodThe Studio at Kendall SquareOff-Target Effects with Matt GlineTech + ToursPlay VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedTOP VIDEO:  Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026 | 01/15/26Quick TakesUpcoming EventsJanuary 11-15 - San Francisco Healthcare Week | San Francisco, CA ​ March 10-11 - Barclays Global Healthcare Conference | Miami Beach, FL ​ May 29 - June 2 - ASCO Annual Meeting | Chicago, IL ​ June 11-14 - EHA2026 Congress | Stockholm, Sweden ​ December 12-15 - ASH Annual Meeting | New Orleans, LA ​ Science Spotlight with Chloe Kirk AI News with Ryan Flinn 01/15/26 - BiotechTV sat down with Yosemite's CEO Reed Jobs to discuss cancer therapeutic investment01/14/26 - Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!01/11/26 - Prices for meeting spaces around Union Square are so expensive during JPM, one VC firm is hosting meetings in a bus Join the BiotechTV mailing listEmail JoinThanks for subscribing!Latest VideosPlay VideoFacebookTwitterPinterestTumblrCopy LinkEmbed VideoLink CopiedFrom NYSE: Annovis Bio CEO Maria Maccecchini shares an update on the oral small molecule buntanetap, which is currently in a pivotal for Alzheimer's02/02/2026Play VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedOut Now: Jonathan Norris' 2025 Full-Year Venture Healthcare Report:  Get the ReportSponsoredPlay VideoFacebookTwitterPinterestTumblrCopy LinkEmbed VideoLink CopiedFrom NYSE: NYSE Market Strategist Eric Criscuolo discusses how the newly appointed Federal Reserve Chair and other market factors might affect the biotech sector02/02/2025Play VideoFacebookTwitterPinterestTumblrCopy LinkEmbed VideoLink CopiedFrom NYSE: Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology02/02/2025Play VideoFacebookTwitterPinterestTumblrCopy LinkLink CopiedBiotech CEO Sisterhood Co-Founders Sheila Gujrathi and Julia Owens talk about the creation of the Biotech CEO Sisterhood and its next steps02/02//2025Shows Around Kendall Square What's new at BiotechTV - from our founderPlay VideoPlay Video11:28SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026Play VideoPlay Video08:19SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions | 01/13/26Play VideoPlay Video15:01SF Healthcare Week: Summit Therapeutics has filed for approval on the first indication of its PD1 x VEGF. Will it live up to its promise and set the next standard for cancer care?Play VideoPlay Video10:23Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead | 01/13/26Play VideoPlay Video11:55SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO | 01/16/25Play VideoPlay Video10:51SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetesPlay VideoPlay Video10:04SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year | 01/15/26Play VideoPlay Video13:04Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week.2026 SF Healthcare WeekPlay VideoPlay Video15:21ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.Play VideoPlay Video09:08ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.Play VideoPlay Video19:01Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XSTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.Play VideoPlay Video09:58ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.Play VideoPlay Video08:29ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.Play VideoPlay Video11:26ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.Play VideoPlay Video11:00ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.Play VideoPlay Video12:14ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.#ASCO25Play VideoPlay Video07:02ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma | 12/8/25Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.Play VideoPlay Video16:50ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I | 12/8/25He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.Play VideoPlay Video19:29ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation | 12/9/25Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.Play VideoPlay Video11:07ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts. | 12/6/25She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.Play VideoPlay Video13:14ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting | 12/8/25He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.Play VideoPlay Video17:45ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis | 12/7/25He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.Play VideoPlay Video12:48ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies. | 12/8/25He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.Play VideoPlay Video10:13ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS | 12/72/25He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.#ASH25Follow BiotechTV@BiotechTVBiotechTVBiotechTVHQ@BiotechTV@BiotechTVHQAlso look for unique social pages for BiotechTV U.SponsorsLearn more about our sponsorsSponsor SpotlightHSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities. ​ ​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.Learn moreGet in TouchContributorsAdvertise: News coverage opportunities:Advertise@BiotechTV.comMediaOppty@BiotechTV.com​Amy BrownUnited Kingdom Area Chris GarabedianBioVenture VoiCesGeneral equiries and feedback:Info@BiotechTV.comBrad LoncarFounderRyan FlinnAI in BiotechJoin our mail listMatt GlineOff-Target EffectsChloe KirkScience CorrespondentDisclosures & PoliciesThank you for watching! 📺bottom of pageenenhttps://biotechtv.com

Edit your site?

What are you doing?